New drug combo offers hope to bladder cancer patients seeking to avoid surgery
NCT ID NCT03504163
Summary
This study tests whether adding the immunotherapy drug pembrolizumab to standard BCG treatment helps control high-risk bladder cancer in patients who want to avoid having their bladder removed. The trial involves 45 participants with early-stage but aggressive cancer that has a high chance of returning. Researchers will measure how many patients remain cancer-free at 6 and 12 months after starting this combination treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, 10065, United States
-
Memorial Sloan Kettering Bergen (All protocol activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack (All protocol activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering West Harrison (All Protocol Activities)
Harrison, New York, 10604, United States
Conditions
Explore the condition pages connected to this study.